Treatment Study of Intracranial Dural Arteriovenous Fistulas

This study is a prospective, multicenter, single-arm study. Patients with dural arteriovenous fistulas (dAVF) have a few choices for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

In order to participate you must meet the following criteria:

• Are between 22 and 80 years of age.
• Are willing and capable of complying with all study protocol requirements, including specified follow-up period.
• Provide written informed consent (subject or authorized legal representative) prior to initiation of any study procedures.
• Have an intracranial dAVF.

You will be excluded from the study if any of the following criteria apply to you:

• Have multiple dAVFs to be treated.
• Have a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
• Have known allergies to dimethylsulfoxide, iodine.
• Are currently participating in another clinical study

This is a partial list of inclusion and exclusion criteria.